

Venue: Exhibition, Ground Level
Presentation: Monday 1 July, 12:30-14:30

The Poster Exhibition is open from Mon 1 - Wed 3 July from 10:00 to 18:30. Posters will be displayed for the duration of the conference.

Authors will stand by their posters between 12:30 and 14:30 on their assigned day of presentation to answer questions and provide further information on their study results.

Track A > Basic Sciences

PE001-004 HIV and SIV diversity

- MOPE001 **Identification and characterisation of a novel HIV-1 CRF53_01B in Malaysia**
W.Z. Chow, Y.M. Lee, H. Abdulrazzaq Abed Al-Darraj, Y. Takebe, A. Kamarulzaman, K.K. Tee Malaysia
- MOPE002 **HIV-1 subtypes and drug resistance mutations among infected patients in Kelantan, Malaysia**
T.A.A. Tengku Mohd Ariffin, Z.Z. Deris, M. Mustafa, S. Mohamad, R.H. Shueb Malaysia
- MOPE003 **Current molecular epidemiology of HIV-1 subtypes in Thailand and the presence of CRF01_AE/B and B/C intersubtype recombinants**
T. Samleerat, P. Suriya, P. Phutthakham, S. Dettrairat, W. Sirirungsi, N. Ngo-Giang-Huong Thailand
- MOPE004 **Identification and characterization of an atypical HIV-1 öineage (CRF54_01B) circulating at low level in Malaysia**
K.T. Ng, L.Y. Ong, Y. Takebe, A. Kamarulzaman, K.K. Tee Malaysia

PE005-006 Variability of transmitted strains

- MOPE005 **HIV-1 genetic diversity and transmitted antiretroviral drug resistance in recently diagnosed Cuban men who have sex with men**
L.Y. Machado, H.M. Díaz, M. Dubed, M. Blanco, N.M. Ruiz, D. Romay, N. Valdés, E. Silva Cuba
- MOPE006 **The molecular epidemiology of HIV-1 infection in Cyprus from 2010 to 2012 revealed an ongoing influx of different HIV-1 lineages and low transmitted drug resistance among antiretroviral naive-infected individuals**
I. Kousiappa, J. Hezka, M. Andreou, I. Demetriades, L.G. Kostrikis Cyprus

PE007-009 Viral dynamics and fitness

- MOPE007 **Characterizing HIV-1 subtype B and CRF01_AE transmission clusters among men who have sex with men (MSM) in Kuala Lumpur, Malaysia**
K.T. Ng, L.Y. Ong, S.H. Razak, Y.M. Lee, Y. Takebe, A. Kamarulzaman, K.K. Tee Malaysia
- MOPE008 **High-resolution evolutionary dynamics of whole HIV-1 genomes in recent infections**
A. Gall, M. Robinson, S. Kaye, S. Fidler, J. Weber, M. McClure, P. Kellam, and the SPARTAC Trial Investigators United Kingdom

- MOPE009 **Dynamics of HIV-1 Gag evolution and transmission of CTL polymorphisms in recently infected patients in Durban, South Africa**
K. Gounder, N. Padayachee, J. Mann, M. van der Stok, M. Mokgoro, M. Jaggernath, P. Goulder, B. Walker, T. Ndung'u South Africa

- PE010-013 Entry (attachment, receptors and co-receptors, penetration and tropism)**
- MOPE010 **Deep sequencing revealed emergence of X4 virus was a cause of but not effect of rapid CD4 decline**
T. Hayashida, K. Tsuchiya, H. Gatanaga, S. Oka Japan

- MOPE011 **HIV-1 entry and -trans--infection in astrocytes: implications for cure and eradication**
L. Gray, S. Turville, W.-J. Cheng, T. Iemma, S. Wesselingh, P. Gorry, M. Churchill Australia

- MOPE012 **Phenotypic determination of HIV-1 envelope tropism using Dual Split Protein (DSP) mediated cell fusion assay system**
N. Hosoya, P. Teeranaipong, S. Heinz, Y. Kashi, A. Kawana-Tachikawa, N. Kondo, H. Hoshino, Z. Matsuda, A. Iwamoto Japan

- MOPE013 **HIV-1 R5 infection favors the expression of the CXCR4 isoform that is the most efficient as a coreceptor: implications for the emergence of CXCR4-using strains**
C. Duquenne, S. Gimenez, C. Psomas, C. Mettling, V. François, P. Corbeau France

- PE014-017 Strategies to target and eradicate reservoirs**

- MOPE014 **HIV resistance to dolutegravir (DTG) simultaneously diminishes viral DNA integration into host cells and viral replication fitness: implications for HIV reservoirs**
T. Mesplede, P. Quashie, M. Oliveira, M. Wainberg Canada

- MOPE015 **Establishment of macaque CD4+ T cells and CD34+ hematopoietic stem cells resistant to SIV infection using Zinc Finger Nucleases technology**
M.-C.E. Gauduin, P. Lentz, G. Bonello, M. Salas, M. Cepeda, R. White United States

- MOPE016 **Activation of the Wnt pathway by natural ligands or small molecule inhibitors activates latent HIV**
H. Rafati, E. LeMasters, V.D.D. Lennert, M. El-Sayyed, C. Boucher, R. Vries, T. Mahmoudi Netherlands

- MOPE017 **Inducing HIV-1 in latently infected T cells with an autologous full length HIV-1 representing the majority intrapatient virus population**
E. Arts, Y. Gao, D. Canaday, T. Biru, G. Nickel, M. Quinones-Mateu United States

- PE019-021 HIV drug development**

- MOPE019 **Study of increased oxidative stress during highly active antiretroviral therapy of HIV/AIDS: potential antioxidative effects of Hibiscus cannabinus Linn**
K. Karale, G. Shinde, M. Muddeshwar India

MOPE020	Antiviral activity of 5-Hydroxytyrosol, a microbicidal candidate <i>L.M. Bedoya, M. Beltrán, D. Auñon, E. Gomez-Acebo, J. Alcamí</i> Spain	MOPE029	Bioequivalence of darunavir (800mg) co-administered with cobicistat (150mg) as either a fixed-dose combination tablet or as single agents under fasted and fed conditions in healthy volunteers <i>T.N. Kakuda, T. van de Castele, R. Petrovic, M. Opsomer, F. Tomaka, J. Mrus, R.M.W. Hoetelmans</i> United States
MOPE021	Evaluation of a panel of selective inhibitors of PKCβ or Lck for controlling HIV-1 replication in CD4$^{+}$ T cells <i>M.R. Lopez-Huertas, J. Hedgpeth, E. Mateos, M. Sanchez del Cojo, J. Swindle, J. Alcamí, M. Coiras</i> Spain	MOPE030	The pharmacokinetics of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) in the presence of the antimycobacterial rifabutin <i>H.M. Crauwels, R. Van Huijkelom, C. Truyers, M. Stevens, J. Mrus, R.M.W. Hoetelmans</i> United States
PE022-023	Mechanisms of anti-retroviral drug resistance	MOPE031	Prevalence of potential drug-drug interactions involving antiretroviral drugs in Buenos Aires, Argentina <i>E. Cordova, N. Porteiro, E. Loiza, H. Mingrone</i> Argentina
MOPE022	Secondary resistance mutations in the R263K integrase inhibitor resistance pathway <i>T. Mesplède, M.A. Wares, N. Osman, P.K. Quashie, Y. Han, D.N. Singhroy, M.A. Wainberg</i> Canada	MOPE032	Factors influencing plasma tenofovir concentrations in HIV-infected adults: effect of low body weight, chronic hepatitis C and proximal tubular dysfunction <i>N. Thammajaruk, J. Sophonphan, R.A. Ramautarsing, K. Praditpornsilpa, Y. Avihingsanon, S. Phonphitak, T. Cresey, D. Burger, K. Ruxrungham, A. Avihingsanon, HIV-NAT 114 Study Team</i> Thailand
MOPE023	In vitro selection of HIV-1 CRF08_BC resistant variants to reverse transcriptase inhibitors <i>H. Wu, X.-M. Zhang, B. Zheng</i> China	MOPE033	Pharmacokinetic (PK) interactions between boceprevir (BOC) and atazanavir (ATV/r) or raltegravir (RAL) in HIV/HCV-co-infected patients (pts). ANRS HC27 study <i>R. Garraffo, ANRS HC 27 BOCEPRE VIH Study Group</i> France
PE024	Bioinformatic analysis in drug resistance	MOPE034	Polymorphisms in the cellular drug transporter P-glycoprotein 1 (ABCB1 gene) are associated with HAART failure <i>J. Dias, M. Arruda, R. Brindeiro, O. Ferreira, A. Tanuri, R.S. Aquiar, C.C. Cardoso</i> Brazil
MOPE024	Analysis of N348I mutation in the connection domain of HIV-1 reverse transcriptase and impact in the efficacy of zidovudine and non-nucleoside reverse transcriptase inhibitors <i>J.C. Mendez, J.D. Yao</i> United States	MOPE035	Prevalence and type of drug-drug interactions involving antiretrovirals in patients attending a specialist outpatient clinic in Kampala, Uganda <i>K. Seden, C. Merry, H. Robert, M. Siccardi, M. Lamorde, P. Byakika-Kibwika, E. Laker, D. Back, R. Parkes-Ratanshi, S. Khoo</i> United Kingdom
PE025	Design of approaches targeting inflammation/immune activation	MOPE036	A large population pharmacokinetic evaluation of the influence of demographic and HIV disease factors on the pharmacokinetics of elvitegravir, cobicistat and tenofovir <i>J.M. Custodio, T. Gordi, F. Jin, X. Wei, Y.-P. Liu, A. Plummer, M. Rhee, J. Szwarcberg, B.P. Kearney, S. Ramanathan</i> United States
MOPE025	Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals <i>J. van Lunzen, J. Kiepe, S. Hertling, A. Hüfner, O. Degen, S. Schmiedel, T. Feld, M. Kurowski, A. Zoufaly</i> Germany		
Track B >	Clinical Sciences		
PE026-036	Pharmacology, pharmacokinetics, pharmacogenomics, role of therapeutic drug monitoring, drug interactions		
MOPE026	Tenofovir plasma concentrations related with creatinine clearance changes particularly in association with LPV/r in first-line regimen of African patients in Cameroon and Senegal: ANRS 12115 DAYANA sub-study <i>G. Peytavin, S. Koulla-Shiro, P. Lê Minh, P.-S. Sow, B. Ndiaye, M.B. Koita Fall, C. Essomba, A. Benalycherif, P.-M. Girard, R. Landman, ANRS 12115-DAYANA- Study Group</i> France		
MOPE027	Efavirenz/tenofovir/emtricitabine levels in colonic tissue <i>D.M. Asmuth, A.D. Kashuba, E.P. Acosta, A. Albanese, X.-D. Li, P. Troia-Cancio, R. Pollard</i> United States	PE037	Pharmacokinetics and outcomes of ARV in women during and after pregnancy including option B+
MOPE028	Predictors of daily tenofovir exposure in Thai subjects taking protease inhibitor-based combination antiretroviral therapy <i>S.J. Kerr, N. Thammajaruk, A. Colbers, M. Gorowara, S. Phonphitak, J. Ananworanich, K. Ruxrungham, D. Burger, A. Avihingsanon</i> Thailand	MOPE037	Atazanavir in pregnancy: transplacental transfer and neonatal hyperbilirubinaemia <i>J. Lambert, V. Jackson, M. Lawless, W. Ferguson, M. Eogan, M. Brennan, L. Else, S. Khoo</i> Ireland
		PE038-040	Non-pregnant women including menopause, contraception

MOPE038	Participation of women in clinical studies pertinent to HIV cure <i>R. Johnston</i> United States	MOPE047	Pharmacokinetics and 24-weeks efficacy of once daily darunavir/ritonavir in virologic suppressed HIV-infected Thai children: a pilot study <i>K. Chokeyphaibulkit, S. Rungmaitree, K. Lapphra, T. Narkbunnam, W. Phongsamart, O. Wittawatmongkol, T. Cressey</i> Thailand
MOPE039	Two cases of breast tenderness and female hormone fluctuations in women of child-bearing age starting Stribild (FTC/TDF/COBI/ELV) <i>S. Scholand, R.D. Bruce</i> United States	PE048-050	Complications of HIV and its therapy including impact on growth, development and neurocognition
MOPE040	Gender differences in immunologic recovery among virologically suppressed HIV/AIDS patients <i>J. Bukulu Sempa, A.N. Kiragga, B. Castelnuovo, A. Kambugu, M.R. Kamya, Y.C. Manabe</i> Uganda	MOPE048	Will it matter when we start? Age at start of antiretroviral therapy (ART) and reversal of stunting <i>R. Parchure, B. Miladinovic, T. Darak, P. Emmanuel, V. Kulkarni</i> India
PE041	Diagnosis of HIV disease including early diagnosis in infancy	MOPE049	HIV and childhood disability: a case-controlled study at a paediatric ART centre in Lilongwe, Malawi <i>A. Devendra, A. Makawa, P.N. Kazembe, N.R. Calles, H. Kuper</i> Malawi
MOPE041	Performance of the World Health Organization clinical algorithm for symptomatic HIV infection among hospitalized HIV-exposed Malawian infants: CD4 count outperforms clinical algorithm <i>M. Maliwichi, E.D. McCollum, N. Rosenberg, R. Macfie, M. Hosseinipour, D. Olson, I. Hoffman, C.M. Van der Horst, P.N. Kazembe</i> Malawi	MOPE050	Nutritional supplementation in HIV-infected children in resource-limited settings <i>M. McHenry, A. Dixit, R. Vreeman</i> United States
PE042	HIV exposed uninfected children	PE052-054	Opportunistic infections, non-HIV related infections and malnutrition
MOPE042	In utero HAART exposure associated with decreased growth among HIV-exposed uninfected breastfed infants in Botswana <i>K.M. Powis, L. Smeaton, W. Fawzi, A. Ogwu, E. Machakaire, S. Souda, K. Wirth, J. Makhema, S. Lockman, M. Essex, R.L. Shapiro</i> United States	MOPE052	Measles among HIV-infected children attending the pediatric HIV clinic at Baylor, Uganda <i>V. Korutaro, V. Tukei, F. Baruga, B. Asiimwe, A. Kekitiinwa, Baylor -Uganda research team</i> Uganda
PE043-047	Pharmacology, pharmacokinetics, drug formulations	MOPE053	Prevalence of opportunistic infections in children undergoing antiretroviral therapy at Baylor College of Medicine Children's Foundation-Uganda, Mulago Hospital <i>P. Kasirye Gitta, A. Asiimwe, V. Korutaro, F. Baruga, S. Bakeera-Kitaka, A. Kekitiinwa</i> Uganda
MOPE043	Random lopinavir concentrations predict virologic failure in a cohort of South African children <i>R.R. Moholisa, M. Schomaker, L. Kuhn, S. Meredith, L. Wiesner, A. Coovadia, M. Leigh, E. Abrams, G. Maartens, H. McIlleron, Neverest Study</i> South Africa	MOPE054	Trends of recovery from wasting among HIV-positive children enrolled into care over the past five years at Baylor-Uganda <i>F. Nabwire, A. Maganda, K. Kyampaire, V. Tukei, B. Nsangi, E. Tumweheire, A. Kekitiinwa</i> Uganda
MOPE044	Update from Study A4001031: maraviroc pharmacokinetics in CCR5-tropic HIV-1-infected children aged 2 to < 18 years <i>M. Vourvahis, L. McFadyen, T. Checchio, C. Giaquinto, L. Keet, S.R. Valluri, A. Fang, G. Mukwaya, J. Heera</i> United States	PE055-061	ARV management strategies – cohort studies
MOPE045	Association of SCL01B1 polymorphism and plasma concentration of lopinavir in HIV-infected children <i>P. Udomchaisakul, C. Srichomthong, N. Thammajaruk, S. Tongkobpetch, P. Sornchai, J. Wongsawat, J. Sophonphan, J. Intasan, K. Suphapeetiporn, T. Puthanakit, PEARL Study Group</i> Thailand	MOPE055	Virologic failure and predictors among HIV-infected adults receiving long-term first-line antiretroviral treatment in 8 provinces in China <i>Y. Ma, F. Zhang, D. Zhao, D. Sun, W. Liu, H. Li, A. Liu, G. Peng, C. Yuan, J. Fan, X. Liu, Z. Liu, N. Wang</i> China
MOPE046	The pediatric dispersible tablet with a FDC of 3TC/NVP/AZT is bioequivalent to the combination of Retrovir® syrup, Epivir® solution and Viramune® suspension providing simplified adaptable dosing for pediatric patients <i>I. Bhushan, A. Deshmukh, S. Chakraborty, C. Rajashekar, A. Jaiswal, R. Kakaria, A. Kanda, P. Deshpande, E. Patras, R. Satapathy</i> India	MOPE056	Outcomes of adolescents and young adults receiving antiretroviral therapy in Soweto, South Africa <i>F. Laher, S. Hornschuh, K. Otjombe, L. Mohapi, A. Violari, G. Gray</i> South Africa
		MOPE057	Care and treatment values, preferences and attitudes of adolescents living with HIV <i>K. Fox, R. Baggaley, J. Ferguson, K. Noto</i> Switzerland

MOPE058	Temporal trends in patient characteristics and outcomes from ART programmes in resource-limited settings <i>A. Grimsrud, L. Myer, S. Balkan, E. Casas, J. Lujan, G. Van Cutsem, E. Poulet, M. Pujades</i> South Africa	PE068-075	Cardiovascular disease (including lipid abnormalities hypertension and smoking)
MOPE059	Comparison of baseline characteristics and antiretroviral treatment outcomes between early, mid and late adolescents: a multicentre cohort study from South Africa <i>G. Fatti, E. Mothibi, B. Eley, A. Grimwood</i> South Africa	MOPE068	Cardiac steatosis (the fatty heart) in cardiovascularly asymptomatic persons with HIV infection <i>S. Lai</i> United States
MOPE060	Impact of using plasma HIV RNA viral load test before switching to second-line antiretroviral treatment (ART) <i>N. Thiha, N. Win, N. Samsi Phong, T. Linn, J. Moe, S. Ko Ko Zaw, W. Maung, M. Shwe, A. Thidar, E. Nerrienet, F. Xavier Babin, N. Steenkeste, P. Clevenbergh</i> Myanmar	MOPE069	Prevalence of dyslipidemia and cardiovascular risk factors amongst patients receiving WHO recommended first- and second-line antiretroviral regimens in western India <i>A. Makane, A. Acchra, V. Bele, K. Joshi, D. Dabhade, A. Chitalikar, A. Mule, M. Law, S. Pujiari</i> India
MOPE061	Factors associated with CD4 >=350 and/or being on ART among adolescent women living with HIV in Zimbabwe <i>M. Dunbar, O. Chang, D. Nhamo, I. Mudekunya-Mahaka, A. Chingono, G. Kadzirange</i> United States	MOPE070	Re-assessing the cardiovascular risk of abacavir in the Swiss HIV Cohort Study (SHCS) using a flexible marginal structural model <i>J. Young, Y. Xiao, M. Abrahamowicz, E.E.M. Moodie, M.B. Klein, P. Vernazza, E. Bernasconi, A. Cusini, R. Weber, H.C. Bucher</i> Switzerland
PE062-064	Behaviour health outcomes including sexual risks, substance use and poor adherence	MOPE071	Hypertriglyceridaemia is strongly linked to APOA5 1131T>C genotype in Chinese patients taking HAART <i>C.M. Naftalin, M.P. Lee, D. Chan, P. Li, S.S. Lee</i> Hong Kong
MOPE062	Geographical access to maternity care at birth in Ghana <i>J.N.D. Sasraku</i> Ghana	MOPE073	Carotid intima-media thickness (cIMT) in HIV-infected patients in Rio de Janeiro, Brazil: overall and gender analysis <i>A.G. Fonseca Pacheco, B. Grinsztejn, M.D.J. Fonseca, R.I. Moreira, V.G. Veloso, R.K. Friedman, S.W. Cardoso, M. Falcão, J.G. Mill, I. Bensenor, P. Lotufo, D. Chor</i> Brazil
MOPE063	'Lets talk about sex' in HIV-infected adolescents in Rwanda <i>J.I. Van Nuil, B. Asiimwe-Kateera, P. Mutwa, E. Kestelyn, J. Vyankandondera, R. Pool, J. Ruhirimbura, C. Kanakuze, P. Reiss, S. Geelen, J. van de Wijgert, K. Boer</i> United Kingdom	MOPE074	Large and small arterial elasticity in HIV-infected patients with and without antiretroviral therapy <i>M. Kundro, J. Toibaro, G. Viloria, M. Losso</i> Argentina
MOPE064	Interventions for supporting adolescents to safely and effectively disclose HIV serostatus in resource-constrained settings: a systematic review <i>T. Horvath, G.E. Kennedy, M.L. Lindegren, S. Royce, R.C. Baggaley, J.B. Ferguson, H. Azman, Firdaus, G.W. Rutherford</i> United States	MOPE075	Untreated HIV-infected patients display a discrepant coagulation profile with elevated D-dimer levels but reduced platelet aggregation and clot initiation <i>A.K. Hauqaard, T.T. Lund, C. Birch, F. Rønsholt, H. Ullum, J. Gerstoft, P.I. Johansson, S.D. Nielsen, S.R. Ostrowski</i> Denmark
PE065-067	Fat accumulation and lipotrophy	PE076-078	Bone disease
MOPE065	Obesity prevalence and cumulative antiretroviral exposure among HIV-positive adults in clinical care at University of North Carolina (UNC), 2004-2010 <i>P. Menezes, J. Keys, D. Wohl, J. Eron</i> United States	MOPE076	Effects of renal tubular dysfunction on bone <i>L. Hamzah, A. Samarawickrama, L. Campbell, M. Pope, K. Burling, A. Norden, B. Hendry, M. Fisher, Y. Gilleece, K. Walker-Bone, F. Post</i> United Kingdom
MOPE066	Microarray analysis of subcutaneous adipose tissue from healthy HIV-seronegative adults exposed to lopinavir/ritonavir exhibited significant changes in insulin signalling <i>R. Maughan, P. Doolan, S. Ahern, M. Clynes, B. Murphy, A. Kelleher, D. Cooper, P. Mallon, SAMA Study Investigators</i> Ireland	MOPE077	Lower bone mineral density independently associated with both increased bone turnover and HIV-1 infection in HIV-positive subjects compared to HIV-negative subjects <i>A.G. Cotter, C.A. Sabin, S. Simelane, A. Macken, B. Rogers, E. Kavanagh, J.J. Brady, P.W.G. Mallon, 'Understanding the Pathology of Bone Disease in HIV Infected Subjects' (HIV UPBEAT) Study Group</i> Ireland
MOPE067	Weight loss among HIV-positive (+) patients receiving the glucagon-like peptide-1 (GLP) analogue liraglutide <i>S. Guillemj, E. Ding, J. Jackson, M. Harris, J. Montaner, G. Bondy</i> Canada		

MOPE078	<p>Number of different antiretroviral regimens rather than cumulative exposure to antiretrovirals associated with lower bone mineral density in HIV-positive subjects</p> <p><i>A. Cotter, C.A. Sabin, S. Simelane, A. Macken, B. Rogers, E. Kavanagh, J.J. Brady, P.W.G. Mallon, 'Understanding the Pathology of Bone Disease in HIV Infected Subjects' (HIV UPBEAT) Study Group</i> Ireland</p>	MOPE086	<p>Prevalence and risk factors of neurocognitive impairment in a national adult HIV cohort in Hungary</p> <p><i>B. Lakatos, G. Gazdag, D. Bánhegyi, Hungarian HIV Neurocognitive Study Group</i> Hungary</p>
PE079-083	Renal disease	PE087-089	Depression and other psychiatric manifestations
MOPE079	<p>Predictors of renal insufficiency in patients randomized to second-line lopinavir/ritonavir monotherapy vs. tenofovir/lamivudine/lopinavir/ritonavir</p> <p><i>J. Sophonphan, P. Chetchotisakd, W. Munsakul, S. Jirajariyavej, P. Kantipong, W. Prasithsirikul, C. Bowonwatanuwong, S. Sungkanuparph, V. Klinbuayaem, B. Hirschel, K. Ruxrungtham, J. Ananworanich, S.J. Kerr, T. Bunupuradah, HIV STAR Study Group</i> Thailand</p>	MOPE087	<p>Exploring social factors associated with suicidality in HIV/AIDS in Mbarara Uganda</p> <p><i>G.Z. Rukundo</i> Uganda</p>
MOPE080	<p>Comparing regression models to investigate risks factors for chronic kidney disease in a large cohort of HIV-infected patients</p> <p><i>F. Rouibah, P. Pugliese, L. Cuzin, C. Isnard-Bagnis, A. Cabié, P. Flandre</i> France</p>	MOPE088	<p>Reliability, validity and factorial congruence of SF-36 Health Survey in Mexican HIV-positive patients</p> <p><i>V. Rodriguez, H. Vega, G. Hernandez, C. Ramirez, J. Cruz, J. Casillas</i> Mexico</p>
MOPE081	<p>The effect of HIV infection, ART and ageing on renal function in PLHIV, Chelsea and Westminster Hospital London, UK, 1996-2012</p> <p><i>S. Mandalia, S. Westrop, K. Farrington, N. Imami, M. Nelson, B. Gazzard, E.J. Beck</i> United Kingdom</p>	MOPE089	<p>Prevalence of depression among HIV-infected adult patients on highly active antiretroviral therapy (ART) at the Botswana-Baylor Children's Clinical Centre of Excellence (BBCCOE)</p> <p><i>T. Marukutira, A. Sathyamoorthi, M. Boitshwarelo, R. Sello, M. Marape, G. Anabwani</i> Botswana</p>
MOPE082	<p>Incidence of end stage renal disease in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)</p> <p><i>K. Althoff, A. Abraham, M. Estrella, H.M. Crane, A. Freeman, M.J. Gill, E.T. Golub, M. Horberg, L.P. Jacobson, M.M. Kitahata, R. McKaig, F. Palella, C.R. Parikh, R.D. Moore, Y. Jing, B. Rodriguez, J. Eron, S. Napravnik, M. Silverberg, A. Mayor, Z. Krishnasami, G. Lucas, North American AIDS Cohort Collaboration on Research and Design</i> United States</p>	PE090-092	Other adverse reactions and complications of ARV therapy
MOPE083	<p>Estimating kidney function in HIV-infected adult individuals in a resource-constrained setting: comparison of different equations and the impact of body weight</p> <p><i>L. Phirum, T. Sopheak, K. Chindamony, S. Pichsovannary, P. Thong, L. Lynen, J. van Griensven</i> Cambodia</p>	MOPE090	<p>The feasibility of switching efavirenz (EFV)-based highly active antiretroviral therapy to raltegravir (RAL)-based therapy in HIV-infected individuals with central nervous system (CNS) toxicity: a phase IV open label pilot study</p> <p><i>H.M. Yapa, L. Waters, J. Rowlands, A. Jackson, S. Mandalia, C. Higgs, M. Boffito, M. Nelson</i> United Kingdom</p>
PE084-086	HIV associated neurocognitive disorders (HAND) and other neurologic disorders	MOPE091	<p>Incidence and causes of early morbidity following initiation of antiretroviral therapy in rural South Africa</p> <p><i>P.C. Mutevedzi, R.J. Lessells, M.-L. Newell</i> South Africa</p>
MOPE084	<p>Neurocognitive impairment (NCI) in HIV-1 infected adults in Sub-Saharan Africa: a systematic review and meta-analysis</p> <p><i>A.G. Habib, A.M. Yakasai, L.F. Owolabi, A. Ibrahim, Z.G. Habib, M. Gudaji, K.M. Karaye, D.A. Ibrahim, I. Nashabaru</i> Nigeria</p>	MOPE092	<p>Incidence and risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy</p> <p><i>J. Yeap, S. Kumar, H.M. Koh, C. Lee</i> Malaysia</p>
MOPE085	<p>Prevalence, incidence and risk factors for peripheral neuropathy in DART trial participants in Uganda and Zimbabwe</p> <p><i>S.K. Muyingo, B. Kikaire, I.K. Mambule, C.F. Gilks, J. Levin, A.S. Walker</i> United Kingdom</p>	PE093-094	HIV aging and frailty
		MOPE093	<p>Effect of age on CD4+ cell recovery, mortality and loss to follow-up during antiretroviral therapy (ART) in Lusaka, Zambia</p> <p><i>M. Vinikoor, J. Joseph, P. Musonda, A. Mwango, L. Mulenga, C. Bolton, J. Eron, B. Chi</i> Zambia</p>
		MOPE094	<p>Changes in telomere length after three years of darunavir/ritonavir monotherapy with and without nucleoside analogues in the MONET trial</p> <p><i>A. Solomon, S. Tennakoon, E. Leeansyah, J. Arribas, A. Hill, Y. van Delft, C. Moeklinghoff, S. Lewin</i> Australia</p>
		PE095	Therapeutic vaccine and immune based therapy trials

MOPE095	An intervention targeting gut microbiota and enterocyte barrier in HIV-infected patients decreased bacterial translocation <i>S. Serrano-Villar, J.F. Vázquez, A. Vallejo, M.J. Gosalbes, M. Vera, A. Latorre, T. Sainz, J. Romero, C. Rodríguez, F. Dronda, A. Moya, S. Moreno, V. Estrada, MicroVIH Study Group Spain</i>	MOPE104	Barriers to pregnancy-related HIV services and PMTCT amongst minorities and migrants in northern Thailand <i>K. Culhane-Pera, P. Kunstadter, R. Thawsirichuchai, W. Yangyuenkun, L. Cha'taw, S. Ayuman, A. Kunstadter, S. Chailert, S. A'pa, P. Klondachonkiri, S. Lecoeur Thailand</i>
PE096 MOPE096	Complementary and traditional medicines Microbial and heavy metal content of selected herbal medicines commonly used by HIV patients in Zimbabwe <i>T.G. Monera, J. Mudzengi, C. Nhachi Zimbabwe</i>	MOPE105	The effect of knowledge on HIV transmission from mother to child on PMTCT uptake in Ogun state, Nigeria <i>B. Olorunnisola, O.K. Fatungase, B.A. Gbadamosi Nigeria</i>
PE097 MOPE097	Strategies for eradication / reservoir depletion 5-drug HAART during primary HIV infection leads to a reduction of proviral DNA levels in comparison to levels achievable during chronic infection <i>E. Wolf, J. Bogner, C. Hoffmann, V. Avettand-Fenoel, K. Schewe, R. Pauli, J. Brust, A. Ulmer, L. Schneider, H. Jaeger Germany</i>	MOPE106	Antenatal HIV testing and counseling practices in seven Asian countries: working towards elimination of MTCT in low and concentrated epidemic settings <i>P. Srikantiah, Y.R. Lo, R. Baggaley, R. Pendse, N. Shaffer Philippines</i>
Track C >	Prevention Science	MOPE107	Using PMTCT as an entry point for ART for clients in discordant relationships: a review of the PMTCT program at St. Theresa Mission Hospital <i>E. Mwila, M. Bwalya, P. Mwansa, D. Miyanda, K. Tshing, G. Kantolomba, K. Sichinga, P. Mulenga Zambia</i>
PE098-099 MOPE098	Reducing pre-partum and intra-partum transmission to infants Are PMTCT programs effective in reducing MTCT? An experience from Mwanza region, Tanzania <i>A. Kigombola, A. Msaki, A. Maghimbi, S. Mwakiyusa Tanzania, United Republic of</i>	PE108-116 MOPE108	Increasing coverage and quality of PMTCT programmes Vertical transmission of HIV less than half among mothers belonging to mother-support groups (MSG) compared to non-member mothers at health centers in Tigray, Ethiopia <i>T. Assefa, M. Abreha, H. Godefay, E. Konings Ethiopia</i>
MOPE099	HIV-free survival and its correlates among HIV-exposed infants in Thai Nguyen, Vietnam <i>V.T.T. Nguyen, K.A. Le Ai, K. Sabin, C. Hayashi, Q.T. Ho, J. Caro, M. Kato Vietnam</i>	MOPE109	Antiretroviral therapy (ART) eligibility assessment and zidovudine and ART initiation in a cohort of HIV+ pregnant women in Mozambique <i>H. Nuwagaba-Biribonwoha, I. Yersin, F. Tsiouris, L. Chongo, M. Okamura, Y. Zhang, D. Horowitz, J. Lima, R.J. Carter, E.J. Abrams United States</i>
PE100-101 MOPE100	Reducing post-partum transmission in infants Overcoming the challenges of early infant diagnosis of HIV: TASO Masindi experience <i>P. Ijotre, I. Anena, Y. Namanya Uganda</i>	MOPE110	Achieving elimination of mother to child HIV transmission in Burundi from the experience of an antenatal care centre in Bujumbura: prospective follow-up of 843 HIV-infected mothers <i>H. Leroy, J.-M. Chapplain, E. Nindagiye, S. Ntizahuvye, J. Biziraguzenyuka, C. Arvieux France</i>
MOPE101	Review of HIV status of exposed babies on extended nevirapine prophylaxis in a resource-limited setting: Ibenga, Zambia <i>E. Mwila, P. Mwansa, M. Bwalya, K. Tshing, J. Mwansa, P. Mulenga, G. Kantolomba, K. Sichinga Zambia</i>	MOPE111	Adherence to the 2010 treatment guidelines for the prevention of mother to child transmission (PMTCT) of HIV in Kenya <i>K. Clark, S. Finocchiaro-Kessler, K. Goggin, S. Khamadi, V. Okoth, B. Gautney United States</i>
PE102-107 MOPE102	Strategies to increase HIV testing in pregnant women and their partners A systematic review of male involvement in HIV programs and reproductive health services <i>F. Kwankam, R. Baggaley, M. Lusti-Narasimhan, N. Shaffer Switzerland</i>	MOPE112	The implementation of Option B +. Sharing unique challenges for refusal to take Option B+ drugs as reported by HIV-infected mothers at Mulago National Referral Hospital, Kampala, Uganda <i>J. Namale Matovu, Z. Namukwaya, M. Mubiru, E. Musinye, M. Kyarimpa, A. Kakande, S. Kanya, P. Musoke, M. Kanya, M.G. Fowler Uganda</i>
MOPE103	Factors associated with antenatal attendance by male partners of HIV-infected women in Nairobi, Kenya <i>A. Aluisio, R. Bosire, C. Farquhar United States</i>	MOPE113	The magnitude of loss to follow-up of HIV-exposed infants along the PMTCT continuum of care: a systematic literature review and meta-analysis <i>E.L. Sibanda, I.V.D. Weller, J.G. Hakim, F.M. Cowan Zimbabwe</i>

- MOPE114 **An investigation of barriers to seeking antenatal care among women in Harare, Zimbabwe: a qualitative study**
E.L. Sibanda, I.V.D. Weller, J.G. Hakim, F.M. Cowan
 Zimbabwe
- MOPE115 **Evaluation of the nutritional status of PMTCT infants in the health district of Dschang Cameroon**
S.S. Martin, F. Joseph, G.W. Raoul Emeric, D.D. Bruna Ghyslaine, C. Vittorio, PS-TEAM Study Group
 Cameroon
- MOPE116 **Inadequate access to interventions to prevent HIV mother to child transmission in a country with a successful program of universal access to HAART**
E. Pires, R. Friedman, L. Camacho, M. Derrico, C. Cunha, R. Moreira, G. Calvet, S. Armesto, M. Santini, V. Veloso, J.H. Pilotto, B. Grinsztejn
 Brazil
-
- PE117-118 Integration of family planning and HIV services**
- MOPE117 **Low uptake of dual contraception methods and high prevalence of unwanted pregnancies among HIV-infected women in Uganda**
I. Nayiga, E.C. Semitala, N. Matsiko, R. Mutumba, C. Nawavvu, J. Namusoby, S. Muhumuza, M.R. Kamy
 Uganda
- MOPE118 **A mixed methods research on fertility desire among people living with HIV in Nepal**
M. Shrestha, A. Aryal
 Nepal
-
- PE120-126 Reproductive choices and interventions for HIV infected women and uninfected women including discordant couples**
- MOPE120 **Relationship status and ART use are predictors of unprotected sex among a sample of harder-to-reach women living with HIV in British Columbia, Canada**
K. Salters, K. Chan, A. Cescon, Y. Chen, S. Patterson, J. Montaner, R. Hogg, A. Kaida
 Canada
- MOPE121 **Integration of peers in the PMTCT and postnatal clinics (PNC), increased subsequent family planning refill visits by HIV-infected women in an urban hospital in Kampala, Uganda**
E. Musinye, P.K. Mudioppe, M. Nakitende, I. Ssekamate, Z. Namukwaya, J. Homsy, M.G. Fowler
 Uganda
- MOPE122 **Uptake and factors influencing uptake of contraceptive implants in the immediate postpartum period among HIV-infected and non HIV-infected women in Mbagathi and Naivasha district Hospitals in Kenya**
M. Shabiby, J. Kinuthia
 Kenya
- MOPE123 **The impact of availability of PMTCT services on hormonal contraceptive use among non-pregnant women of childbearing age in Rakai, Uganda**
L. Litwin, F. Makumbi, R. Gray, G. Kigozi, J. Kagaayi, G. Nakigozi, D. Serwadda, H. Brahmbhatt
 Uganda
- MOPE124 **Fertility desires of pregnant and non-pregnant women before and after availability of PMTCT services in Rakai, Uganda**
L. Litwin, F. Makumbi, R. Gray, G. Kigozi, J. Kagaayi, G. Nakigozi, T. Lutalo, D. Serwadda, H. Brahmbhatt
 Uganda
- MOPE125 **Could misreporting of condom use explain the apparent association between injectable hormonal contraceptives and HIV acquisition risk?**
J. Smith, R. Heffron, C. Celum, J. Baeten, T. Hallett
 United Kingdom
- MOPE126 **Factors associated with gender-based violence and unintended pregnancy among adolescent women living with HIV in Zimbabwe**
D. Nhamo, I. Mudekunya-Mahaka, O. Chang, A. Chingono, G. Kadzirange, M. Dunbar
 Zimbabwe
-
- PE127-128 Establishing cohorts to study HIV incidence, preventive interventions, natural history**
- MOPE127 **High HIV prevalence, incidence and diverse sexual practices in a cohort of male sex workers in Nairobi, Kenya**
L. McKinnon, G. Gakii, J. Juno, P. Izulla, J. Munyao, N. Ireri, C. Kariuki, L. Gelmon, C. Wachih, R. Kaul, R. Lorway, K. Joshua
 Kenya
- MOPE128 **Sexual behaviour and vaginal practices during pregnancy and postpartum: implications for HIV prevention strategies**
J. Kinuthia, K. Odem-Davis, A. Wagner, A. Drake, D. Matemo, J. Unger, G. Ambler, M. Merkel, S. McClelland, G. John-Stewart
 Kenya
-
- PE129-130 Barriers and facilitators to adherence to biomedical HIV prevention strategies**
- MOPE129 **Determinants of antiretroviral treatment adherence among women accessing PMTCT "Option B+": a retrospective study at Bwaila Hospital, Malawi**
W.F. Ng'ambi, H. Tweya, C. Speight, C. Man-Bourdon, M. Hosseinpour, S. Phiri
 Malawi
- MOPE130 **Profile of minority HIV vaccine participants: lessons learned from phase I & II HIV vaccine trials to increase minority participation**
A. Alio, C. Lewis, K. Mufhandu, I. Tariku, M. Keefer, C. Bunce
 United States
-
- PE131-134 Pre-exposure prophylaxis (systemic)**
- MOPE131 **HIV pre-exposure prophylaxis: pharmacists knowledge, perception and willingness to adopt future implementation in a Zimbabwean urban setting**
C. Moffat Joel Matyanga, S. Khoza, S. Gavi
 Zimbabwe
- MOPE132 **Attitudes towards pre-exposure prophylaxis (PrEP) among MSM in Germany**
I. Krznanic, N. Hanhoff, P. Ingiliz, A. Bodtlaender, G. Knecht
 Germany
- MOPE133 **Vulnerable infected populations and illicit markets for ARVs: potential implications for PrEP rollout in the U.S.**
S. Kurtz, H. Surratt, M. Buttram
 United States

MOPE134	Modelling HIV PrEP in humanized mice: pharmacokinetic studies on antiretroviral drugs raltegravir, tenofovir and maraviroc <i>R. Akkina, M. Veselinovic, C.P. Neff, J. Lecureux, L. Mulder, A. Kashuba</i> United States	MOPE142	HIV shedding in semen of men who have sex with men on efficient cART is associated with high HIV-DNA levels in PBMC but not with residual HIV-RNA viremia (ANRS EP49) <i>J. Ghosn, A. Delobelle, M. Leruez-Ville, C. Beaudoux, L. Mascard, A. Canestri, R. Landman, D. Zucman, D. Ponscarne, A. Rami, J.-P. Viard, B. Spire, H. Lecuyer, D. Costagliola, C. Rouzioux, M. Suzan-Monti</i> France
<hr/>			
PE135-138	Post-exposure prophylaxis (systemic)		
MOPE135	Safety, tolerability and adherence with raltegravir-emtricitabine-tenofovir as HIV non-occupational post-exposure prophylaxis in men who have sex with men <i>J. McAllister, A. McNulty, P. Read, W. Tong, A. Ingersoll, A. Carr</i> Australia	MOPE143	The cascade of care in the eastern European country of Georgia <i>N. Chkhartishvili, O. Chokoshvili, L. Sharvadze, J. Dehovitz, C. del Rio, T. Tsertsvadze</i> Georgia
MOPE136	Uptake and repeat use of post-exposure prophylaxis in a community-based clinic in Los Angeles, California <i>M. Beymer, R. Bolan, R. Flynn, D. Kerrone, D. Pieribone, S. Kulkarni, R. Landovitz</i> United States	MOPE145	Supporting clinical evidence for "minimal interference" as a guiding concept for selecting ART for HIV prevention <i>B. Lebouché, K. Engler, J.J. Lévy, N. Gilmore, B. Spire, W. Rozenbaum, J.-P. Routy</i> Canada
MOPE137	Preliminary data from a pilot program of non-occupational post-exposure prophylaxis in Vancouver, British Columbia (BC), Canada <i>J. Pai, W. Michelow, W. Zhang, G. Colley, M. Harris, V. Montessori, S. Guillemi, I. Day, J. Montaner, M. Hull</i> Canada	PE146	Pharmacology of ARVs for HIV prevention (PK, PD)
MOPE138	Eleven years experience of prophylaxis after sexual exposure to HIV at Clinique L'Actuel - Montreal <i>R. Thomas, S. Vézina, D. Sissoko, D. Longpré, M. Boissonnault, E. Huchet, M. Jean, L. Charest, B. Trottier, N. Machouf</i> Canada	MOPE146	Effects of maternal tuberculosis (TB) treatment on nevirapine (NVP) concentrations among neonates receiving NVP for prevention of mother to child transmission of HIV: the TSHEPISO study team <i>H. McIlleron, N. Martinson, D. Paolo, F. Mashabela, J. Hunt, S. Shembe, R. Msandiwa, S. Velaphi, C. Silvia, R. Chaisson, K. Dooley</i> South Africa
<hr/>			
PE139-170	HIV testing in couples	PE147	Blood, organ, tissue and medical injection safety
MOPE139	Factors affecting acceptance of couple HIV counselling and testing: retrospective review of The AIDS Support Organization (TASO) Apac BHCT/Malaria 3 years project data-PEPFAR funded project, Northern Uganda <i>L. Ssali, F. Wasagaami, J. Birungi, M. Ochow, M. Etukoit, R. Wanyama</i> Uganda	MOPE147	The viral infections and blood use for mothers and children under five years in Sierra Leone <i>S. Baker, A. Adeyemo, M. Yilla, M. Kabba, S. Nam, I. Kamara</i> Sierra Leone
MOPE169	The characteristics of HIV serodiscordant couples tested in Zambia and implications on prevention activities <i>C. Kwok, E. Dissen, M. Inambao, W. Kilembe, J. Abdallah, W.-H. Kuo, A. Tichacek, P. Chadd, N. Munir, K. Parris, S. Allen</i> Zambia	PE148-157	Male circumcision
MOPE170	Trends in couples' HIV counseling and testing uptake and HIV status disclosure among HIV-positive couples in Rakai, Uganda <i>J. Matovu, J. Ssekasanvu, F. Nalugoda, D. Serwadda</i> Uganda	MOPE148	HIV prevention: using the SurgiPex technique for adult male circumcision <i>J.P. Bitega, M. Vincent, K. Kayondo, L.M. Ngeruka, A. Gasana</i> Rwanda
PE141	Pre- and post-exposure prophylaxis (topical) / microbicides	MOPE149	Medical male circumcision improves HIV prevention services access <i>P. Athieno, D. Kwarisiima, A. Kwikiriza, C. Nawavvu, J. Namusoby, M. Kanya</i> Uganda
MOPE141	Thermosensitive gel delivery of rilpivirine nanoparticles prevents vaginal HIV-1 acquisition <i>J. Long, C. Destache, M. Swanson, A. Date, J.V. Garcia</i> United States	MOPE150	Surgical and programmatic efficiencies triple the number of clients circumcised within a year of implementation: experience from the Rwanda Defense Forces <i>K. Curran, E. Rugwizangoga, J. Zoungrana, C. Murego, J. Sinzaherā, A. Mutabaruka, B. Mukarugwiro, E. Zimulinda</i> Rwanda
PE142-145	Treatment as prevention	MOPE151	Effects of medical male circumcision on HIV viral load in HIV+ HAART naïve men; Rakai, Uganda <i>G. Kigozi, R. Musoke, N. Kighoma, N. Kiwanuka, F. Makumbi, E. Nalugoda, D. Serwadda, N. Sewankambo, F. Wabwire Mangen, S. Watya, M. Wawer, R.H. Gray</i> Uganda

MOPE152	<p>Factors associated with early resumption of sexual activity after voluntary medical male circumcision: a review of the effectiveness of MC counseling at two sites in Zambia</p> <p><i>W. Kanjipite, M. Lukobo, J. Nikisi, K. Asiedu, C. Hiner</i> Zambia</p>	MOPE161	<p>Feasibility of HIV universal voluntary counseling and testing in a general practice clinic of a Thai tertiary care center</p> <p><i>T. Khawcharoenporn, A. Apisarnthanarak, K. Chunloy, K. Smith</i> Thailand</p>
MOPE153	<p>Male circumcision, wound healing in HIV-negative and HIV-positive men with low CD4 counts in Rakai, Uganda</p> <p><i>G. Kigozi, R. Musoke, N. Kighoma, S. Watya, N. Kiwanuka, F. Nalugoda, F. Makumbi, D. Serwadda, J. Nkale, N. Sewankambo, F. Wabwire Mangen, G.K. Nalwoga, G. Nakigozi, M. Wawer, R.H. Gray</i> Uganda</p>	MOPE162	<p>Should we make HIV testing more convenient for gay men?</p> <p><i>I. Zablotska, M. Yang, M. McKechnie, G. Prestage, G. Brown, B. Maycock, C. Fairley, J. de Wit</i> Australia</p>
MOPE154	<p>Cost analysis of the PrePex procedure compared to surgical procedure</p> <p><i>V. Mutabazi, C. Karema, J.P. Bitega, L.M. Ngeruka, F. Mugabo, S.A. Kaplan</i> Rwanda</p>	MOPE163	<p>HIV detection and linkage to care: BCN checkpoint, a community-based centre for MSM in Catalonia, Spain, achieves high detection of HIV and 90,5% coefficient of linkage to care</p> <p><i>M. Meulbroeck, J. Saz, E. Ditzel, H. Taboada, F. Pérez, A. Pérez, A. Carrillo, P. Coll, G. Font, G. Marazzi, J. Uya, J. Cabrero, M. Ingrami, R. Marín, F. Pujol</i> Spain</p>
MOPE155	<p>A multicentric qualitative study about male circumcision practices in India from the perspectives of community and health care providers</p> <p><i>S. Sahay, K. Nagarajan, S. Mehendale, S. Deb, A. Gupta, S. Bharat, S. Bhatt, B.K. Athokpam, V. Kanthe, A. Sinha, N. Chandhiok</i> India</p>	MOPE164	<p>Should HIV testing be offered to all presumptive TB cases in settings with a low-level HIV epidemic?</p> <p><i>A. Kumar, A. Kanchar, D. Gupta, R.S. Gupta, R. Raghuram, A. Sreenivas</i> India</p>
MOPE156	<p>Factors associated with post-operative follow-up after voluntary medical male circumcision at twelve health facilities in five districts in Nyanza Province, Kenya</p> <p><i>A. Oyanga, J.L. Kulzer, T. Odeny, K. Owuor, P. Oyaro, C. Kirui, G. Nyanaro, C.R. Cohen, E.A. Bukusi</i> Kenya</p>	MOPE165	<p>Investigating recent testing among MSM: results from community-based HIV rapid testing attendees in France</p> <p><i>K. Champenois, N. Lorente, J. Blanche, M. Mora, J.-M. Le Gall, M. Suzan-Monti, M. Préau, Y. Yazdanpanah, B. Spire</i> France</p>
MOPE157	<p>Referrals by community-based lay counselors in Mozambique increase utilization of voluntary medical male circumcision services</p> <p><i>J. Comé, L. Macarringue, M. Mahomed, D. Bossemeyer, E. Necochea, B. Cummings, J. Cardoso, H. Muquinge, T. Ferreira, A. Balate, K. Curran</i> Mozambique</p>	MOPE166	<p>Coordinating HIV testing with combination prevention: a new strategic direction for the CDC Mozambique program</p> <p><i>D. Shodell, N. Honwana, J. McOwen</i> United States</p>
PE158	<p>STI control to prevent HIV transmission</p>	MOPE167	<p>Reaching new HIV testers: experiences from home-based counseling and testing in a rural district in Kenya</p> <p><i>C. Muchira, M. Kitheka, S. Gitia, J. Muraya, M. Kabue, P. Wamae, I. Malonza</i> Kenya</p>
MOPE158	<p>Undetectable viral load among PLWHA two years after starting HAART in Brazil, 2011</p> <p><i>A.I.A. de Sousa, J.M. Givisiez, A.R.P. Pascom, M.R. de Arruda, M.A. de Freitas, A.A. Pereira, A.R. Costa, H.B. Bernal, R. Hallal, R. Burgos, D.B. Greco</i> Brazil</p>	MOPE168	<p>Socioecological barriers to HIV testing among black heterosexual men and black men who have sex with men in Chicago: implications for improving HIV testing in high-risk groups</p> <p><i>A. Murphy, R. Bhatia, N. Moore, I. Martin, C. Hollowell, C. Achenbach, R. Kittles</i> United States</p>
PE159-168	<p>Novel approaches for HIV testing</p>	Track D >	<p>Operations and Implementation Research</p>
MOPE159	<p>HIV testing in clinical indicator diseases in outpatient settings: offer and uptake rates and impact of educational and active interventions</p> <p><i>O. Dosekun, S. Perera, T. Sanghera, M. Hayes, A. Bexley, S. Goubet, J. Roberts, N. Perry, M. Fisher</i> United Kingdom</p>	PE171-180	<p>Impact evaluation of different models of service delivery (cost effectiveness of different strategies, comparative effectiveness studies)</p>
MOPE160	<p>Falling through the cracks? Characteristics of undiagnosed HIV infections and implications for HIV testing for injection drug users and street-based sex workers</p> <p><i>K. Vasarhelyi, K. Shannon, K. Deering, K. Chan, A. Simo, R. Gustafson, M.W. Tyndall, T. Kerr, J.S.G. Montaner, E. Wood</i> Canada</p>	MOPE171	<p>Clinical effectiveness of a strategy to manage GeneXpert negative HIV-infected patients with presumptive TB in Uganda</p> <p><i>S. Walusimbi, F.C. Semitala, M. Onyango, A. Kunihira, J. Namusobya, M.L. Joloba, J.L. Davis, M.R. Kanya</i> Uganda</p>

- MOPE172 **Timing of referral approaches to recruit men who have sex with men (MSM) into an HIV cohort study in Bangkok, Thailand: implications for prevention programming**
W. Wimonasate, S. Chaikummao, P. Luechai, K. Pancharoen, S. Hengprasert, P. Khlaimanee, N. Tippanont, A. Varangrat, C.S. Todd, A. Chitwarakorn, T.H. Holtz, T. Chemnasiri
 Thailand
- MOPE173 **Costing analysis of national HIV treatment and care program in Vietnam**
A. Duong Thuy, M. Kato, S. Bales, N. Do Thi, T. Nguyen Thi Minh, T. Cao Thi Thanh, L. Nguyen Thanh
 Vietnam
- MOPE174 **The effect of behaviour change campaigns on HIV incidence: lessons from sexual network simulations**
S.L. Tolentino, W. Delva
 South Africa
- MOPE175 **Excellent outcomes of the Thailand national antiretroviral treatment universal coverage program in over 200,000 HIV-infected adults**
K. Ruxrungham, A. Avihingsanon, S. Pinyakorn, C. Narkpaichit, W. Sawasdivorn, Y. Suchonwanich, S.J. Kerr, S. Bhakeecheep, on behalf of the NHSO, NAP Program
 Thailand
- MOPE176 **A comparison of treatment outcomes between ART services in district hospital and rural health centers: a prospective cohort study in a rural district, Zambia**
J. Watata, C. Dube, T. Kato, Y. Yasutaka, K. Komada, S. Miyano, A. Mwango, I. Sikazwe, G. Syakantu
 Zambia
- MOPE177 **A cost analysis of the expansion of antiretroviral treatment to the rural health centre level through mobile HIV services in Zambia**
I. Sikazwe, A. Mwango, K. Komada, S. Miyano, C. Scott, G. Syakantu
 Zambia
- MOPE178 **CD4 below 500: increase of ART patients and the financial impact in Brazil**
A. Guimarães, F. Viegas Neves da Silva, R. Hallal, D. Greco
 Brazil
- MOPE179 **Which clinic factors determine clinical outcomes on antiretroviral therapy (ART) in patients attending primary health clinics in South Africa?**
S. Charalambous, A. Grant, G. Churchyard, R. Mukora, K. Fielding
 South Africa
- MOPE180 **Cost-effectiveness of three HIV counseling and testing strategies among male most-at-risk-population in Nigeria**
F. Ukwuije, G.I. Eluwa, S.B. Adebajo, A. Oginni, B. Ahonsi, J. Njab, S. Abdu-Aguye
 Nigeria
-
- PE181-182 **Integrating prevention interventions with care/treatment services including new models of service delivery**
- MOPE181 **Initiation of voluntary medical male circumcision (VMMC) at one hospital in Lesotho increases new HIV diagnoses and uptake of ART among men**
V.M. Kikaya, L. Skolnik, J. Nkonyana, K. Curran, T.A. Ashengo, M.C. Garcia
 Lesotho
- MOPE182 **Challenges of delivering quality post rape care services in public health facilities in Kenya**
S.N. Njenga, A. Gatuguta, C. Mugenyi, N. Kilonzo
 Kenya
-
- PE183-190 **Provider and facility characteristics that determine clinical and prevention outcomes**
- MOPE183 **Gender inequities in IAS-USA HIV clinical care outcomes among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000-2010)**
A.J. Carter, J.E. Min, W. Chau, V.D. Lima, N. Pick, J.S.G. Montaner, R.S. Hogg, A. Kadia
 Canada
- MOPE184 **Early warning indicators for HIV drug resistance in adult and pediatric antiretroviral therapy sites in Kenya: results of a national survey**
E. Nquai, S. Masyuko, I. Mukui, A. Katana, A. Waruru, A. Gichangi, R. Mpazanje, B. Ngeno, S. Vakil, R. Wafula, I. Mohammed, L. Nganga
 Kenya
- MOPE185 **Discrete choice experiment highlights heterogeneous HIV testing preference in Tanzania**
J. Ostermann, B. Njau, D. Brown, A. Mühlbacher, A. Weinhold, E. Reddy, N. Thielman
 United States
- MOPE186 **Efficiencies in the performance of voluntary medical male circumcision (VMMC) procedures**
D. Rech, J. Reed, S. Frade, C.A. Samkange, N. Thomas, M. Farrell, D. Castor, E. Njeuhmeli, J. Bertrand
 South Africa
- MOPE187 **Association between patients' immunologic outcomes and program/facility characteristics in Nigeria**
C.C. Ugoji, R. Ake-Uzoigwe, M.Y. Ladele, G. Mendy, M. Charurat, P. Dakum, H. Isah, O. Nwanyanwu, W. Blattner
 Nigeria
- MOPE188 **Community-based organizations (CBO) HIV treatment programmes in urban Burkina Faso: initial mortality and its predictors**
N. Meda, A.S. Sanou, D. Dahourou, I. Tiendrebeogo, C. Koala, L.T. Ouedraogo, J.Y. Drabo
 Burkina Faso
- MOPE189 **The clock is ticking: timely ART initiation in Kenya at 60 nationally-representative health facilities**
T. Odeny, A. Gasasira, A. Haakenstad, K. Moore, B. DeCenso, S. Masters, R. Burstein, E. Dansereau, E. Okiro, P. Njuguna, C. Kisia, S. Kumar, M. Hanlon, H. Duber, E. Gakidou
 United States
- MOPE190 **Facility and patient-level determinants of treatment failure among Kenyan adults initiating antiretroviral therapy between 2007 and 2012**
T. Odeny, A. Gasasira, A. Haakenstad, K. Moore, B. DeCenso, S. Masters, R. Burstein, E. Dansereau, E. Okiro, P. Njuguna, C. Kisia, S. Kumar, M. Hanlon, H. Duber, E. Gakidou
 United States
-
- PE191-195 **Methods to improve provider quality, supply and targeting of services (e.g. pay for performance, conditional promotions, user quality assessments)**

- MOPE191 **Effect of an error detection unit in an HIV/AIDS treatment centre dispensary Kampala, Uganda**
P. Ibanda
 Uganda
- MOPE192 **Relationship between quality health-care services and retention rate among HIV care clients in Kwara State, Nigeria**
A. Eshalomi, U. Onyebuchi, E. Abba, O. Orji, B. Dare, K. Omotosho
 Nigeria
- MOPE193 **Implementing a quality improvement program in Zambian Defence Force health facilities as a means to improve retention in the PMTCT cascade**
Y.M. Kim, M. Chilila, J. Mulilo, H. Shasulwe, J. Banda, W. Kanjipite, K. Asiedu, J. Nikisi, S. Sarkar, E. Bazant, C. Hiner, M. Tholandi, S. Reinhardt, A. Kols, S. Stender
 France
- MOPE194 **Results from the analysis of prescription errors in Argentina as part of a program to improve quality of care**
E. Bissio, C. Balleri, C. Falistocco
 Argentina
- MOPE195 **Assessment of quality of life with WHOQOL-HIV BREF and MOS-HIV among HIV patients in Korea**
S.-W. Kim, H.-I. Kim, H.-H. Chang, J.-M. Lee, Y.-J. Kim, W.-K. Lee, M.-Y. Lee
 Republic of Korea
-
- PE196-205 **Health care workers (including volunteers): training, mentoring, retaining, task shifting and ensuring occupational safety**
- MOPE196 **Engaging HIV healthcare providers in online learning through interactive case simulation tools**
D. Wang, A. Luque, X.H. Le
 United States
- MOPE197 **Community perspectives on task-shifting: a multi-country survey to inform WHO consolidated ARV guidelines**
G. Mburu, A. Hsieh, M. Ram, C. Mallouris, E. Negussie, C. Irvine, P. Easterbrook
 United Kingdom
- MOPE198 **Protecting HIV/AIDS health workers against healthcare-associated infections: results from a knowledge, attitude and practices survey among HIV/AIDS healthcare workers in a Ugandan HIV/AIDS service organisation**
F. Wasagami, J.M. Matjila, L. Ssali
 Uganda
- MOPE199 **Occupational exposure to bloodborne pathogens among health care workers in Zambia: reporting and utilization of post-exposure prophylaxis**
D. Selenic, M. Lahuerta, S. Basavaraju, C. Courtenay-Quirk, Y. Liu, F. Soud, E. Msidi, G. Kassa, M. Sakala, M. Kapina, C. Malama, E. Masebe, R. Lungwebungu, N. Bock, Pathways to PEP Collaboration
 United States
- MOPE200 **E-learning supported by group discussions on MSM behaviour in Africa increased knowledge and reduced homophobia among health care providers in Coastal Kenya**
E.M. Van der Elst, E. Gichuru, A. Omar, E. Wahome, Z. DUBY, L.-G. Bekker, S. Baral, B. Bender, D. Operario, A.D. Smith, E.J. Sanders
 Kenya
- MOPE201 **Task shifting works: doctors, clinical officers and nurses perform equally well in VMMC service delivery in Iringa and Njombe regions, Tanzania**
A. Hellar, B. Dorica, M. Plotkin, T. Adamu, H.R. Mahler, K. Curran, A. Maganga, R. Mbagani, S. Mkungume, M. Machaku, S. Koshuma, F. Hezwa, J. Lija
 United States
- MOPE202 **Building the capacity of health care workers to enhance pharmacovigilance for antiretroviral therapy and patient safety**
N. Kusu, J. Kimeu, C. Olwande, J. Pandit
 Kenya
- MOPE203 **The dilemma of building an HIV treatment and care programme on lay counsellors**
M.J. Visser, P. Mabota
 South Africa
- MOPE204 **Rethinking volunteerism in Sub-Saharan Africa: select findings from a mixed-method survey in 758 volunteer HIV caregivers in Zambia**
J. Price, S. Topp, T. Moyo, D. Mulenga, M. Dennis, M. Ngunga
 Zambia
- MOPE205 **Tasking shifting and employee performance in Uganda's health sector: a case study of HIV clinics in Busia district**
J.R. Magongo, G. Karyeja, M. Kaguhangire-Barifajo
 Uganda
-
- PE206-213 **Engaging community in service delivery highlighting models for greater and more meaningful involvement of PLHIVs in HIV and AIDS response**
- MOPE206 **Successful initiation of key population HIV services in Zanzibar**
A. Ussj, A. Khamis, A. Kimwaga, F. Khalid, J. Ward, J. Tiberio, S. Hassan, E. Matiko, D. Mbilinyi
 Tanzania, United Republic of
- MOPE207 **Placing a value on volunteer time: a description of how people living with HIV gain personal value from their involvement in HIV/AIDS response**
E. Ssemmanda, R. Atukunda, B. Nsangi, V. Tukei, A. Kekitiinwa
 Uganda
- MOPE208 **Home-based care for orphans and vulnerable children: can it change the face of vulnerability in southern Africa?**
M.J. Visser, M. Zungu, N. Ndala-Magoro
 South Africa
- MOPE209 **Community perspectives on national considerations in the strategic use of ARVs: a multi-country e-consultation to inform the WHO 2013 consolidated ARV guidelines**
A.K. Teltschik, A. Garner, A. Hsieh, N. Keeble, C. Mallouris, C. Irvine, J. Perriens, G. Mburu, A. Ball
 United Kingdom
- MOPE210 **Advocacy for HIV-TB collaborative policy and service delivery in India: a civil society perspective**
S. Kondreddy, S. Sahay
 India
- MOPE211 **What strategies are feasible at the grassroot to improve PMTCT? Lessons from the ACTION in Community program**
R. Ake-Uzoigwe, H. Isah, P. Dakum, A. Okwuosah, G. Adamu, M. Hamisu, E. Mang, A. Gomwalk, G. Anih
 Nigeria

- MOPE212 **Community AIDS support agents (CASAs) are key players in retention and decongesting large patient Ant retroviral (ART) clinics: a community programme funded by CDC/PEPFER in Uganda**
D. Mpiima, R. Makabayi, J. Birungi, C. Luzze
 Uganda
- MOPE213 **The role of schools in the care of HIV-infected children: perspectives of HIV-infected children and their teachers**
G. Karugaba, V. Mabikwa, T. Marukutira, G. Letamo, M. Marape, J. Makhanda, R. Seleke, G. Anabwani
 Botswana
-
- PE214-218 Feasibility, cost effectiveness and impact of various strategies to integrate HIV interventions with other health programs (TB, RCH/MCH, NCD, IMNCI, malaria)**
- MOPE214 **Delivery of HIV treatment and care within ANC/MNCH care settings in generalized epidemic resource-constrained settings: a systematic review**
H.M. Azman Firdaus, A. Spaulding, D. Bain Brickley, T. Horvath, R.C. Baggaley, A.B. Suthar, E.K. Negussie, G.E. Kennedy, G.W. Rutherford
 United States
- MOPE215 **The influence of integrated TB and HIV service delivery on patient health outcomes**
J. Uyei, D. Coetzee, J. Macinko, S.L. Weinberg, S. Guttmacher
 United States
- MOPE216 **Links between fertility intentions, family planning use and HIV status among postpartum women in Swaziland: lessons from cohort and ethnographic data**
I. Birdthistle, M. Klingel, M. Colombini, J. Kikuvu, C. Warren, S. Mayhew, Integra Initiative team
 United Kingdom
- MOPE217 **Integration of HIV and maternal health care in a high HIV prevalence setting: analysis of client flow data from an evaluation in Swaziland**
I. Birdthistle, S. Mayhew, J. Kikuvu, W. Zhou, K. Church, C. Warren, R. Nkambule, J. Fenty
 United Kingdom
- MOPE218 **Should tuberculosis (TB) clinics provide (or refer for) antiretroviral therapy (ART)? A systematic review**
S. Royce, A.T. Anglemyer, T. Horvath, E. McCarthy, G.E. Kennedy, G.W. Rutherford, R.C. Baggaley, A. Suthar, E.K. Negussie
 Switzerland
-
- PE219 Integrating HIV services with other development programmes (poverty reduction, education, water and hygiene, nutrition)**
- MOPE219 **The impact of household HIV/AIDS on fuel, water and subsistence livelihoods: evidence from the 2008-2009 Kenyan demographic health survey**
E. de Moor
 United States